Search Videos and More
Video
Shayna Sarosiek, MD discusses WM-NET 1 trial
Deep responses following treatment with Ioncastuximab tesirine (WM-NET1 trial) in patients with Relapsed/Refractory including those with high risk, TP53-altered Waldenstrom macroglobulinemia.
Video
Maria Capilla Guerra, MD discusses rapid diagnosis of acute leukemia with integrated epigentic and genetic profiling
News
Twenty-Five Years of Progress in Cancer
As we close out the first quarter of the twenty-first century, it isn’t hard to notice how much the world has changed since the year 2000. Smartphones. Social media. Artificial intelligence.
News
Dana-Farber Cancer Institute and Dana-Farber/Boston Children’s Cancer and Blood Disorders Center recognized for exceptional outcomes in donor stem cell transplants
Dana-Farber Cancer Institute’s adult stem cell transplant program and Dana-Farber/Boston Children’s Cancer and Blood Disorders Center’s pediatric stem cell transplant program have once again received exceptional ratings from the Center for International Blood & Marrow Transplant Research (CIBMTR), earning a +1 performance score, the highest possible designation, on their annual center-specific survival reports.
Document
Tip Sheet: Medication-Related Osteonecrosis of the Jaw
The Breast Oncology Center developed this reference for providers caring for patients with medication-related osteonecrosis of the jaw in November 2025.
Video
Erica Mayer, MD discusses results from TBCRC 56 study
Erica Mayer, MD, of Dana-Farber Cancer Institute shared results from TBCRC 56, showing presurgical treatment with a PARP inhibitor + anti-PD1 combo in patients with gBRCAm early triple-negative breast cancer resulted in a pCR rate of 50%. Further ongoing correlative work may identify the best candidates for this non-chemo approach.
Video
Paolo Tarantino, MD discusses the DATO - Base study
Paolo Tarantino, MD, of Dana-Farber Cancer Institute, presented new findings from the DATO-Base study examining treatment with the ADC Dato-DXd for women with leptomeningeal disease. Breast cancer is the most common cancer linked to this rare but serious condition.
Video
Rachel Freedman, MD discusses phase 2 ATOP study
Dana-Farber Cancer Institute's Rachel Freedman, MD, presents results from the phase 2 ATOP study showing older patients with HER2+ breast cancer receiving adjuvant T-DM1 had a favorable 5-year survival with manageable toxicity. ATOP is the 1st adjuvant trial for older patients with HER2+ breast cancer in the United States.
Video
Ann Partridge, MD discusses YES study
Breast cancer survivors who used a novel mobile health intervention to self-manage post-treatment symptoms were able to improve their quality of life and reduce the burden of common symptoms, according to results of the YES study presented by Ann Partridge, MD, of Dana-Farber Cancer Institute.
Video
Stefania Morganti, MD discusses ctDNA study
Ultrasensitive detection of minimal residual disease using ctDNA can help predict the duration of response to HER2 targeted therapy in patients with metastatic breast cancer, according to a study presented by Stefani Morganti, MD, of Dana-Farber Cancer Institute.
News
Dana-Farber Research Supports FDA Approval of T-DXd Plus Pertuzumab for First-Line Treatment of HER2+ Metastatic Breast Cancer
The U.S. Food and Drug Administration (FDA) has approved trastuzumab deruxtecan (T-DXd) in combination with pertuzumab for first-line treatment of metastatic HER2-positive breast cancer.
News
Dana-Farber Research News 12.15.2025
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from November 16 - 30.